As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition ...

The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...

Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free ...

Keytruda plus platinum-based chemotherapy was found to be both safe and efficacious in treating penile squamous cell carcinoma (PSCC), according to findings from the phase 2 HERCULES trial presented ...

This segment offers an up-to-date overview of current treatment standards and diagnostic practices in advanced esophageal ...

Bengaluru: For years, oral cancer in India has been viewed through the lens of male tobacco use, even though women in parts ...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

Indian researchers found gene patterns that may improve diagnosis and treatment for oral cancer in women, offering new hope ...

Phase I clinical trials remain essential for new drug development, identifying new treatment pathways, and identifying optimal dosing, the American Society of Clinical Oncology emphasized in a new ...